Abstract
The substituted-cysteine accessibility method (SCAM) was applied to transmembrane span seven of the human A1 adenosine receptor (hA1AR) to reveal a subset of amino acids that are exposed to the ligand-binding crevice. The SCAM approach involved a systematic probe of receptor structure by individual substitutions of residues K265 (7.30) to R296 (7.61) with cysteine. In most cases, hA1AR substituted-cysteine mutant membranes displayed antagonist dissociation binding constants that did not differ significantly from wild-type (WT). Radioligand binding assays were used to compare cell membranes that were treated with hydrophilic, sulfhydryl-specific methanethiosulfonate derivatives with control cell membranes. Position H278 was previously reported to be required for A1AR ligand binding; however, that report did not establish that H278 represents a contact point for ligands. Cysteine-substitution at H278 yields membrane preparations with greatly decreased receptor density compared with WT membranes from cells in the same transfection experiment. However, H278C membranes retain a measurable fraction of antagonist binding. This observation allows for the investigation of binding-crevice accessibility at position 278 and suggests that H278 may not be required for binding of antagonist ligands. Our data reveal the binding-crevice accessibility of residues T270 (7.35), A273 (7.38), I274 (7.39), T277 (7.42), H278 (7.43), N284 (7.49), and Y288 (7.53) in the hA1AR. These data are consistent with the high-resolution structure of bovine rhodopsin that features three α-helical turns in this region that are interrupted by an elongated, nonhelical structure from positions 7.43 to 7.48 in the primary amino acid sequence.
Footnotes
- Received November 6, 2000.
- Accepted February 6, 2001.
-
Send reprint requests to: Dr. Jack N. Wells, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6600. Email:jack.wells{at}mcmail.vanderbilt.edu
-
This work was funded through the American Heart Association Southeast Affiliate Grant-in-Aid and National Institutes of Health Grants R01-GM55813 and GM07628.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|